Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Swiss Exchange  >  Cosmo Pharmaceuticals N.V.    COPN   NL0011832936

COSMO PHARMACEUTICALS N.V.

(COPN)
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector newsAnalyst Recommendations

Cosmo Pharmaceuticals NV : annual earnings release

share with twitter share with LinkedIn share with facebook
share via e-mail
0
03/26/2019 | 09:15am EST

The company will report its earnings for FY 2018 on 03/29/2019. Generally, the company reports earnings better than estimates. In recent months, the 2 analysts from Thomson Reuters consensus have revised their EPS estimates downward.

Annual earnings per share is expected at -1.41 EUR for 2018 (- 35.8% from 2017). A summary of annual publications and estimates is available below.

Annual results2015201620172018 (e)2019 (e)
Sales
Million €
Released
Forecast
Spread
60,6
60,3
0,56%
67,7
64,7
4,6%
67,2
62,9
6,9%

69,3

79,5
Operating income (EBITDA)
Million €
Released
Forecast
Spread
0,97
-4,12
124%
24,0
18,3
32%



-15,3

-22,7
Operating profit (EBIT)
Million €
Released
Forecast
Spread
-7,53
-15,5
51%
21,0
14,1
49%
-15,5
-13,4
-16%

-18,5

-33,0
Pre-Tax Profit (EBT)
Million €
Released
Forecast
Spread


27,5
10,7
157%
-32,4
-36,1
10%

-17,6

-32,6
Net income
Million €
Released
Forecast
Spread
248
248
0,08%
19,3
6,62
192%
-32,4
-32,1
-1,2%




EPS
 €
Released
Forecast
Spread
17,2
17,6
-2,0%
1,37
0,47
194%
-2,19
-2,00
-9,3%

-1,41

-2,70
Announcement Date03/23/201603/24/201703/26/2018
Stocks mentioned in the article
ChangeLast1st jan.
COSMO PHARMACEUTICALS N.V. 0.41% 73.5 Delayed Quote.-16.72%
THOMSON REUTERS CORPORATION 1.37% 94.04 Delayed Quote.40.71%

© MarketScreener.com 2019
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on COSMO PHARMACEUTICALS N.V.
12/02COSMO PHARMACEUTICALS N : announces worldwide exclusive Distribution Agreement f..
AQ
12/02Cosmo Pharmaceuticals announces worldwide exclusive Distribution Agreement fo..
TE
11/26COSMO PHARMACEUTICALS N : appoints New CSO; as current CSO retires
PU
11/26Cosmo appoints New CSO as current CSO retires
TE
11/05Cosmo's Partner RedHill announces approval of Talicia for the treatment of H...
AQ
11/04Cosmo's Partner RedHill announces approval of Talicia® for the treatment of H..
TE
11/04Cosmo's Partner RedHill gibt die Zulassung von Talicia® für die Behandlung vo..
TE
10/21Cosmo licenses Aemcolo for the USA to RedHill Biopharma and takes a 19.56% st..
AQ
10/21RedHill Announces $36 Million Strategic Investment by Cosmo Pharmaceuticals a..
AQ
10/18Cosmo licenses Aemcolo™ for the USA to RedHill Biopharma and takes a 19..
TE
More news
Financials (EUR)
Sales 2019 47,1 M
EBIT 2019 -17,4 M
Net income 2019 -27,6 M
Finance 2019 117 M
Yield 2019 -
P/E ratio 2019 -36,4x
P/E ratio 2020 -91,8x
EV / Sales2019 18,3x
EV / Sales2020 9,74x
Capitalization 980 M
Chart COSMO PHARMACEUTICALS N.V.
Duration : Period :
Cosmo Pharmaceuticals N.V. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends COSMO PHARMACEUTICALS N.V.
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 4
Average target price 101,86  €
Last Close Price 67,03  €
Spread / Highest target 104%
Spread / Average Target 52,0%
Spread / Lowest Target 5,65%
EPS Revisions
Managers
NameTitle
Alessandro E. Della Chà Chief Executive Officer & Executive Director
Mauro Severino Ajani Chairman
Giuseppe Cipriano Chief Operating Officer
Niall Donnelly Chief Financial Officer & Head-Investor Relations
Luigi Moro Chief Scientific Officer
Sector and Competitors
1st jan.Capitalization (M$)
COSMO PHARMACEUTICALS N.V.-16.72%1 084
JOHNSON & JOHNSON8.14%367 304
ROCHE HOLDING AG25.10%263 429
MERCK AND COMPANY16.15%225 956
PFIZER-12.88%210 463
NOVARTIS21.74%207 450